* Theravance Biopharma Inc TBPH.OQ TBPH.O is expected
to show
a fall in quarterly revenue when it reports results on August
4.
* The George Town Grand Cayman-based company is expected to
report a 3.9% decrease in revenue to $12.413 million from
$12.91 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Theravance
Biopharma Inc
is for earnings of 11 cents per share. For the same quarter last
year, the company reported a loss of 80 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Theravance
Biopharma Inc is $10, above its last closing price of $8.79.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.11 -0.11 -0.22 Missed -107.5
Dec. 31 2022 -0.32 -0.33 -0.43 Missed -29.7
Sep. 30 2021 -0.56 -0.56 -0.48 Beat 14.1
Jun. 30 2021 -1.02 -1.00 -0.80 Beat 19.9
Mar. -1.05 -1.05 -1.24 Missed -18.3
31 2021
Dec. 31 2020 -1.02 -1.02 -0.92 Beat 9.4
Sep. 30 2020 -0.99 -1.01 -1.16 Missed -14.5
Jun. 30 2020 -0.98 -0.98 -1.00 Missed -2.4
This summary was machine generated July 30 at 00:40 GMT. All
figures in US dollars unless otherwise stated